PharmGen Science팜젠사이언스

PharmGen Science posted a large trailing net loss in H1 2026 despite a small operating profit, and its shares have fallen sharply over the past year.

PharmGen Science is a Seoul-based pharmaceutical company that also sells health products and leases out a building it owns. On trailing twelve-month figures to H1 2026 it had revenue of about ₩175B and a small operating profit of about ₩4.2B, but a net loss of about ₩134B, which the data does not explain. The shares closed at ₩2,785 on 19 October 2026, down 31.3% over one year and near the lower half of their 52-week range.

What stands out

• Trailing revenue of about ₩175B is roughly flat with 2025 (₩173B), and 2025 growth was only 1%.
• Operating income fell from ₩10.7B in 2024 to ₩6.0B in 2025, and trailing operating income is about ₩4.2B, a 2.4% margin.
• Net income swung from a ₩7.0B profit in 2024 to a ₩117B loss in 2025 and a ₩134B trailing loss; the filings extracted here do not give the cause.
• The stock trades at about 0.5 times book value and 0.4 times sales, with no P/E because of the losses, and pays no dividend.
• Cash of about ₩19.5B is reported with no borrowings listed, and foreign ownership is small at 1.5%.

What to watch

• The full-year 2026 results and the explanation behind the large net loss, which the data does not give.
• Any further filings on the amended annual report and the May 2026 share-related disclosures, including conversion and new share rights.
• Whether the company's revenue and operating profit hold up in coming reports, given the weak trailing earnings.